Caseware UK (AP4) 2024.0.164 2024.0.164 2025-03-312025-03-31true2024-04-01true1false1falseNo description of principal activityThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006. 06691375 2024-04-01 2025-03-31 06691375 2022-10-01 2024-03-31 06691375 2025-03-31 06691375 2024-03-31 06691375 c:Director1 2024-04-01 2025-03-31 06691375 d:CurrentFinancialInstruments 2025-03-31 06691375 d:CurrentFinancialInstruments 2024-03-31 06691375 d:CurrentFinancialInstruments d:WithinOneYear 2025-03-31 06691375 d:CurrentFinancialInstruments d:WithinOneYear 2024-03-31 06691375 d:ShareCapital 2025-03-31 06691375 d:ShareCapital 2024-03-31 06691375 d:RetainedEarningsAccumulatedLosses 2025-03-31 06691375 d:RetainedEarningsAccumulatedLosses 2024-03-31 06691375 c:FRS102 2024-04-01 2025-03-31 06691375 c:AuditExemptWithAccountantsReport 2024-04-01 2025-03-31 06691375 c:FullAccounts 2024-04-01 2025-03-31 06691375 c:PrivateLimitedCompanyLtd 2024-04-01 2025-03-31 06691375 e:PoundSterling 2024-04-01 2025-03-31 iso4217:GBP xbrli:pure

Registered number: 06691375










PHARMA TACTICS LIMITED








UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 31 MARCH 2025

 
PHARMA TACTICS LIMITED
 

CONTENTS



Page
Accountants' report
 
 
1
Balance sheet
 
 
2
Notes to the financial statements
 
 
3 - 4


 
PHARMA TACTICS LIMITED
 
  
CHARTERED ACCOUNTANTS' REPORT TO THE DIRECTOR ON THE PREPARATION OF THE UNAUDITED STATUTORY FINANCIAL STATEMENTS OF PHARMA TACTICS LIMITED
FOR THE YEAR ENDED 31 MARCH 2025

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of Pharma Tactics Limited for the year ended 31 March 2025 which comprise  the Balance sheet and the related notes from the Company's accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW)we are subject to its ethical and other professional requirements which are detailed at https://www.icaew.com /regulation.

This report is made solely to the director of Pharma Tactics Limited in accordance with the terms of our engagement letter dated 28 November 2017Our work has been undertaken solely to prepare for your approval the financial statements of Pharma Tactics Limited and state those matters that we have agreed to state to the director of Pharma Tactics Limited in this report in accordance with ICAEW Technical Release TECH07/16AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Pharma Tactics Limited and its director for our work or for this report. 

It is your duty to ensure that Pharma Tactics Limited has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and profit of Pharma Tactics Limited. You consider that Pharma Tactics Limited is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or review of the financial statements of Pharma Tactics Limited. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.

  


BAGINSKY COHEN
CHARTERED ACCOUNTANTS
930 HIGH ROAD
LONDON
N12 9RT
12 August 2025
Page 1

 
PHARMA TACTICS LIMITED
REGISTERED NUMBER: 06691375

BALANCE SHEET
AS AT 31 MARCH 2025

2025
2025
2024
2024
Note
£
£
£
£

  

CURRENT ASSETS
  

Cash at bank and in hand
 4 
5,376
15,703

Creditors: amounts falling due within one year
 5 
(1,808)
(1,731)

NET CURRENT ASSETS
  
 
 
3,568
 
 
13,972

  

NET ASSETS
  
3,568
13,972


CAPITAL AND RESERVES
  

Called up share capital 
  
1
1

Profit and loss account
  
3,567
13,971

  
3,568
13,972


The director considers that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of comprehensive income in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 12 August 2025.



H. ROSENBERG
Director

The notes on pages 3 to 4 form part of these financial statements.

Page 2

 
PHARMA TACTICS LIMITED
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025

1.ACCOUNTING POLICIES

 
1.1

BASIS OF PREPARATION OF FINANCIAL STATEMENTS

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The preparation of financial statements in compliance with FRS 102 requires the use of certain critical accounting estimates. It also requires management to exercise judgment in applying the Company's accounting policies (see note 2).

The following principal accounting policies have been applied:

 
1.2

REVENUE

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

 
1.3

TAXATION

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.


 
1.4

CASH AND CASH EQUIVALENTS

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
1.5

CREDITORS

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

 
1.6

DIVIDENDS

Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting.

Page 3

 
PHARMA TACTICS LIMITED
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025

2.



JUDGMENTS IN APPLYING ACCOUNTING POLICIES AND KEY SOURCES OF ESTIMATION UNCERTAINTY

In the application of the company’s accounting policies, which are described in note 1, management is required to make judgements, estimates and assumptions about the carrying values of assets and liabilities that are not readily apparent from other sources. The estimates and underlying assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.
The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods. 


3.


EMPLOYEES

The average monthly number of employees, including directors, during the year was 1 (2024 - 1).


4.


CASH AND CASH EQUIVALENTS

2025
2024
£
£

Cash at bank and in hand
5,376
15,703



5.


CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

2025
2024
£
£

Corporation tax
837
554

Other creditors
71
97

Accruals and deferred income
900
1,080

1,808
1,731



Page 4